Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Brian Cox

Chuen Chan

Malcolm Stuart Nobbs

Gita Punjabhai Shah

Joanna Victoria Geden

Suzanne Elaine Keeling

Stephen Swanson

Alison Judith Redgrave

Frank Ellis

David George Allen

Richard Peter Charles Cousins

Heather Hobbs

Mark Patrick Healy

Hazel Joan Dyke

David E Bays

Colin David Eldred

Caroline Mary Cook

Dean David Edney

Michael Simon Loft

Thomas Davis Roper, Iv

Richard Peter Charles

Michael David Barker

Shiping Xie

Caroline Whitworth

Andrew Michael Kenneth Pennell

Andrew Michael Pennell

Richard Charles Peter Cousins

Deborah Wild

There are provided according to the invention, novel compounds of formula (I) wherein R , R and R are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory disease.

2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

There are disclosed according to the invention, compounds of formula (I) wherein R , R and R are defined in the specification. Additionally, processes of preparing the compounds of formula (I), formulations containing same, and the administration of said compounds or formulations thereof in the treatment of inflammatory diseases are also disclosed.

2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives

Pyrazine compounds

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.

2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives

A compound of formula (I) wherein R is phenyl substituted by one or more halogen atoms; R is &mdash;NH ; R is &mdash;NH or hydrogen; R is &mdash;CXNR R , &mdash;CXNH&mdash;(CH ) &mdash;NR R ; wherein X is &boxH;O or &plus;S; y is an integer zero, 1 or 2; R and R , which may be the same or different, are selected from hydrogen and C alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle containing one or two nitrogen heteroatoms, which heterocycle can be further substituted with one or more C alkyl groups; and pharmaceutically acceptable derivatives thereof.

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2 receptor are described.

2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives

Triazine compounds for treatment of CNS disorders

A compound of formula (I) which is an agonist at the adenosine A1 receptor wherein R represents C alkyl, halogen or hydrogen; R represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the adenosine A1 receptor.

Chemical Compounds

There are provided according to the invention novel compounds of formula (I) wherein R , R , and R are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

A compound of formula (I) and pharmaceutically acceptable prodrugs, salts and solvates thereof.

A compound of formula (I) wherein R,is selected from the group consisting of phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R,is selected from the group consisting of &mdash;NH,and &mdash;NHC(&boxH;O)R,; R,is selected from the group consisting of &mdash;NR,R,, &mdash;NHC(&boxH;O)R,and hydrogen, R,is selected from the group consisting of hydrogen, -C,alkyl, -C,alkyl substituted by one or more halogen atoms, &mdash;CN, &mdash;CH,OH, &mdash;CH,OR,and &mdash;CH,S(O),R,; wherein R,represents C,alkyl or C,cycloalkyl, and R,and R,, which may be the same or different, are selected from hydrogen and C,alkyl, or together with the nitrogen atom to which they are attached, form a,-membered nitrogen containing heterocycle, which heterocycle can be further susbtituted with one or more C,alkyl; R,is selected from C,alkyl or C,alkyl substituted by one or more halogen atoms; x is an integer zero, one or two; and pharmaceutically acceptable derivatives thereof; with the proviso that R,does not represent (a); when R,is &mdash;NH,, and both R,and R,are hydrogen.

Adenosine derivatives

Growing community of inventors

Stevenage, United Kingdom

Brian Cox